Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00133731 · ClinicalTrials.gov registry record · Phase 2
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 947
- Enrollment target
NCT00133731: Completed Phase 2 study, sponsored by Sanofi.
NCT00133731 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 947 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (612% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00133731, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 947 participants
- Enrollment target
Study Summary
The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
Interventions
- PROCEDURE Percutaneous Coronary Intervention
- DRUG Otamixaban (XRP0673)
- DRUG Unfractionated Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 947 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00133731 record still lists
NCT00133731 is an interventional study that assigns participants to a tested intervention. The registered 947 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (612% higher).
The record links to 0 conditions, and to 3 interventions - of which Percutaneous Coronary Intervention is the first listed.
NCT00133731 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00133731 about?
NCT00133731 is a clinical study titled "The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention". The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
What is the current status of trial NCT00133731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 947 participants. The study started on 2004-09. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00133731?
The interventions under investigation include: Percutaneous Coronary Intervention (PROCEDURE), Otamixaban (XRP0673) (DRUG), Unfractionated Heparin (DRUG).
Who is sponsoring clinical trial NCT00133731?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00133731's enrollment target sits among peer trials
947 29th of 2000 higher than 1,972 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia